Administrative Policy effective January 1, 2020

Return to Provider News

Ranitidine by Glenmark Pharmaceuticals, Inc. Recall

Audience: Providers of Impacted Patients

Glenmark Pharmaceutical Inc. announced the voluntary recall of all unexpired lots of ranitidine tablets, 150 mg and 300 mg, to the consumer level. The recalled lots of ranitidine tablets 150 mg and 300 mg are being recalled because of the presence or potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake levels established by the FDA, based on FDA-validated tests. To date, Glenmark has not received any reports of adverse events that have been confirmed to be directly related to this recall.

A list of your patients who may have filled a prescription for ranitidine over the last four months is printed on the bottom of this notice. We have notified these patients of the ranitidine recall and advised them to contact you to discuss possible alternative medications to treat their health condition, or to contact Glenmark Drug Safety at 1-888-721-7115.

Thank you for the level of care and service that you provide to our members. 

Related News
Hemlibra Requires Prior Authorization Effective October 1

Hyaluronic Acid Preferred Therapy Update

Medicare MS-DRG Payment Add-On for COVID-19 Hospitalizations

Eyewear Benefit Clarification for MMC and HARP Members

Metformin ER Recall